Key Takeaways MRK's Winrevair met the primary endpoint in the CADENCE study in adults with CpcPH tied to HFpEF.Winrevair cut pulmonary vascular resistance at 24 weeks versus placebo, with safety in line with known data.MRK plans to present results at a future conference and advance Winrevair to phase III in this populationMerck (MRK) announced that the phase II CADENCE study, which evaluated its newly launched pulmonary arterial hypertension (“PAH”) drug Winrevair, for treating adults with combined post and ...